Julie Overton | executive |
Maria Zannes | executive |
Michael Edwards | executive |
Steven Silver | analyst |
Good morning, and welcome to the bioAffinity Technologies Fourth Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Julie Anne Overton, Director of Corporate Communications. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to today's conference call to discuss bioAffinity Technologies fourth quarter and full year 2022 financial results and our recent business progress. Please note that certain information discussed during today's call is covered under the safe harbor provision of the Private Securities Litigation Reform Act.